Amgen To Extend Enbrel Cancer, Autoimmune Safety Study By Five Years
This article was originally published in The Pink Sheet Daily
The company satisfied a prior post-marketing commitment to collect five-year data on cancer and autoimmune disease development but will now extend that follow-up period to a total of 10 years, an FDA approval letter for labeling revisions to the TNF inhibitor says.
You may also be interested in...
New language on lymphoma in the Warnings and Adverse Reactions sections of labeling is substantially similar to that of other TNF-inhibitors – Amgen's Enbrel and Abbott's Humira. J&J is issuing a "Dear Doctor" letter to inform physicians of the changes.
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.